U.S. FDA proposes new COVID-19 prevention strategy

The US Food and Drug Administration wants to simplify the Covid-19 vaccine process to a single booster dose with an updated bivalent Covid-19 vaccine.
According to a statement released by the FDA, “an updated bivalent Covid-19 vaccine provides broad protection against Covid-19 and is expected to provide better protection against Covid-19 caused by the currently circulating Omicron variant.”
“The bivalent Covid-19 vaccines include a component of the original virus strain to provide broad protection against Covid-19 and a component of the omicron variant to provide better protection against Covid-19 caused by the omicron variant,” the FDA statement continues.
The recommendation aims to keep protection against Covid-19 up to date, with consideration given to the fact that the virus changes over time.
On January 26th, the FDA Vaccines and Related Biological Products Advisory Committee will meet to consider whether and how the composition for primary doses of the current Covid-19 vaccines should be modified. They will also discuss whether booster doses should be adjusted moving forward.